<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23497">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02063113</url>
  </required_header>
  <id_info>
    <org_study_id>RC13_0437</org_study_id>
    <nct_id>NCT02063113</nct_id>
  </id_info>
  <brief_title>Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.</brief_title>
  <acronym>MYELOME-PA</acronym>
  <official_title>Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether the presence of vulnerability detected by
      geriatricians is associated with treatment discontinuation in older patient. During the
      comprehensive geriatric assessment realized before the decision-treatment, the following
      data are recorded and their impact in the therapeutic changes will also be analysed:
      comorbidity, age, depression, functional status, the cognitive impairment and malnutrition.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>The occurrence of the events</measure>
    <time_frame>6 MONTHS</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary outcome is either :
early interruption of treatment
dose reduction &gt; 20% during treatment
discontinuous treatment
These outcomes will be measured every 6 months during the 2 years of follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of Vulnerability</measure>
    <time_frame>6 MONTHS</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>vulnerability related to toxicities, vulnerability related to multiple myeloma or geriatric vulnerability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic changes</measure>
    <time_frame>6 MONTHS</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>early interruption of treatment, dose reduction during treatment, discontinuous treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity during treatment</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>hematologic toxicity, neurotoxicity, gastrointestinal toxicity, deep vein thrombosis, pulmonary embolism, infections with antibiotic use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression to 1 and 2 years</measure>
    <time_frame>1 year/2year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response at 1 and 2 years</measure>
    <time_frame>1 year/2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Myeloma in Older Patients</condition>
  <arm_group>
    <arm_group_label>NA/NA</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vulnerability and therapeutic changes in older patients with multiple myeloma.</intervention_name>
    <arm_group_label>NA/NA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 70 years and older

          -  Patients referred for a assessment of a newly diagnosed multiple myeloma

          -  Patients for who the initial therapy proposed is either
             melphalan-prednisone-thalidomide or melphalan-prednisone-bortezomib or included in a
             phase 3 trial.

          -  Patients who provide informed written consent

        Exclusion Criteria:

          -  Patients who refuse the study

          -  Patients who won't have therapy

          -  Patients can't respond to geriatric assessment  because of severe cognitive disorder

          -  Patients with a legal guardian
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Komivi AGBETSIVI, DR</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD Vendée La Roche sur Yon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>VIGNARD Patricia, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH du Mans</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Cattenoz, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean -Richard EVEILLARD, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Brest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Puisieux, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean -Yves NIEMIER, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frédérique Retornaz, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CGD de Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Véronique Brunel, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen de Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laure De Decker, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laure De Decker, Dr</last_name>
    <email>laure.dedecker@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure De Decker, Dr</last_name>
      <email>laure.dedecker@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Laure De Decker, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>February 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple myeloma,</keyword>
  <keyword>Older patient,</keyword>
  <keyword>Treatment,</keyword>
  <keyword>Geriatric assessment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
